Similar Items: Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data
- Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis
- Identification of an Immune Cell Gene Signature for Predicting Response and Prognosis in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
- The Predictive Value of Neutrophil‐To‐Lymphocyte Ratio (NLR) for Response to Neoadjuvant Immunochemotherapy in Resectable IIA–IIIB Non‐Small Cell Lung Cancer in Real‐World Practice
- CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing
- MRI‐based qualitative, quantitative, and radiomics/deep learning methods for assessing treatment response after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
- Correction to “Macro Habitat‐Based T2‐Weighted MRI Radiomics and Deep Learning Fusion for Predicting Treatment Response and Prognosis After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer”